Incyte's Opzelura Shows Sustained Efficacy in Moderate Atopic Dermatitis Trial

Event summary

  • Incyte presented 24-week data from the Phase 3 TRuE-AD4 trial of Opzelura (ruxolitinib) cream in adults with moderate atopic dermatitis at the 2026 EADV Symposium.
  • 84.3% of patients in the Opzelura group achieved EASI75 and 70.6% achieved IGA-TS at Week 24, maintaining Week 8 results.
  • Opzelura was well-tolerated with few application site reactions (1.7%) and no new safety signals up to 24 weeks.
  • Incyte aims to work with EU regulators to bring Opzelura to European adults with moderate AD who have progressed on standard topical therapies.

The big picture

Incyte's Opzelura is positioning itself as a differentiated nonsteroidal treatment option for atopic dermatitis, a condition affecting up to 12% of adults worldwide. The sustained efficacy and safety data from the TRuE-AD4 trial could bolster its case with EU regulators, potentially opening a significant market opportunity. The focus on patients who have inadequate responses to standard therapies highlights a strategic push into niche but high-need patient segments.

What we're watching

Regulatory Strategy
Whether Incyte can secure EU approval for Opzelura in moderate atopic dermatitis, expanding its market beyond the U.S.
Market Differentiation
How Opzelura's nonsteroidal profile will position it against existing topical treatments for atopic dermatitis.
Long-Term Efficacy
The pace at which sustained efficacy data will influence prescribing patterns and market adoption.